Helix BioPharma Corp. Announces Changes in Senior Management
December 06 2013 - 4:00PM
Marketwired
Helix BioPharma Corp. Announces Changes in Senior Management
AURORA, ON--(Marketwired - Dec 6, 2013) - Helix BioPharma Corp.
(TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing
innovative drug candidates for the prevention and treatment of
cancer, today announced that it has terminated its employment of
John Docherty, effective immediately.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Investor Relations: Helix BioPharma Corp. Tel: 905 841-2300
Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From May 2024 to Jun 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From Jun 2023 to Jun 2024
